Recombinant factor VIIa
Medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about NovoSeven?
Summarize this article for a 10 year old
Recombinant factor VIIa (rfVIIa) is a form of blood factor VII that has been manufactured via recombinant technology.[4][5] It is administered via an injection into a vein.[6][4][5] It is used to treat bleeding episodes in people who have acquired haemophilia, among other indications.[7] There are several disimilar forms, and biosimilars for each. All forms are activated.
INN | USAN | Brand name | Notes |
---|---|---|---|
Eptacog alfa (activated) | coagulation factor VIIa (recombinant) | Novoseven | Oldest formulation, Baby hamster kidney cells (BHK).[7] |
Eptacog alfa (activated) | coagulation factor VIIa (recombinant) | Novoseven RT | Approved in the US in 2008.[2] BHK cells.[2] |
Eptacog beta (activated) | coagulation factor VIIa (recombinant)-jncw | Sevenfact (US), Cevenfacta (EU) | Biosimilar, produced through rabbit milk.[8] Approved in the EU in 2022.[5] |
This article may be in need of reorganization to comply with Wikipedia's layout guidelines. The reason given is: Information scattered in Medical use and jncw (rabbit) sections. (December 2023) |
Clinical data | |
---|---|
Trade names | Novoseven, Sevenfact, others |
Other names | rFVIIa, Coagulation factor VIIa (recombinant), Coagulation factor VIIa (recombinant)-jncw |
Biosimilars | Aryoseven |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG |
The most common side effects with Novoseven include venous thromboembolic events (problems caused by blood clots in the veins), rash, pruritus (itching), urticaria (hives), fever and reduced effectiveness of treatment.[4] The most common side effects with Cevenfacta include injection site discomfort and hematoma (a collection of blood under the skin) as well as injection-related reactions, an increase in body temperature, dizziness and headache.[5]
Novoseven was approved for medical use in the European Union in February 1996,[4] and in the United States in March 1999.[9]